What is the longevity market actually worth?

Why do longevity market estimates range from billions to trillions?

Longevity market estimates are all over the place because the word “longevity” is being used for several completely different businesses.

At the narrow end, The Business Research Company currently puts the global longevity-clinic market at $5.35 billion. Grand View Research estimates longevity diagnostics at $2.8 billion and anti-aging supplements at $4.8 billion.

Move one step outward and the numbers jump. Grand View values anti-aging products at $55.6 billion, mostly because skincare becomes part of the calculation.

Then the definition gets much broader. The Global Wellness Institute estimates the entire wellness economy at $6.8 trillion. AARP's latest Longevity Economy research says Americans aged 50 and over generated $12.5 trillion of U.S. economic activity in 2024.

Calling all of those figures “the longevity market” creates most of the confusion.

AARP is measuring the economic activity associated with older consumers. The Global Wellness Institute includes industries ranging from fitness to wellness tourism and real estate. Anti-aging market reports often include conventional skincare. Longevity-clinic estimates focus on a much narrower set of medical and preventive services.

So we need to separate three questions: how much people already spend on products explicitly connected to aging, how much they spend on modern healthspan services, and how large the future market for drugs that actually alter aging could become.

Estimate	What it really measures	Scale
AARP Longevity Economy	U.S. economic activity associated with people aged 50+	$12.5T
Global Wellness Institute	Global wellness economy	$6.8T
Anti-aging products	Mostly skincare and beauty products	$55.6B
Anti-aging supplements	Supplements sold around aging-related benefits	$4.8B
Longevity clinics	Dedicated longevity and preventive-health clinics	$5.35B
Longevity diagnostics	Biological-age, omics and related testing	$2.8B
Approved drugs for aging itself	Drugs approved specifically to treat biological aging	Effectively $0

What should we actually count as the longevity market?

A useful definition of the longevity market should include products people buy specifically to stay healthier as they age, while excluding the huge amount of ordinary spending that simply happens to come from older consumers.

That leaves us with several layers.

The broad commercial market includes anti-aging skincare, supplements, diagnostics, longevity clinics and similar products sold directly around aging or healthspan.

Inside that is a more interesting healthspan market: biological-age testing, deeper diagnostics, preventive-health memberships, dedicated longevity clinics, targeted supplements and other services built specifically around maintaining function for longer.

Then we reach longevity biotech, where companies are trying to change the biology of aging itself through drugs, cell therapies, gene therapies or cellular reprogramming.

Those layers behave very differently.

Someone buying an anti-wrinkle serum clearly belongs in the commercial anti-aging economy. Someone paying for an epigenetic-age test fits the modern longevity market more closely. A company developing a drug that rejuvenates old liver cells belongs at the experimental biotech end, even though it may currently have no product sales.

Once we separate those groups, most of the supposed disagreement between market estimates disappears.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

How much money are people actually spending on longevity today?

Broadly defined, consumers are already spending roughly $60 billion to $70 billion a year on products and services explicitly connected to aging.

Grand View Research's latest estimate puts anti-aging products at $55.6 billion. Its separate anti-aging supplement category adds $4.8 billion, while longevity diagnostics add another $2.8 billion. The Business Research Company currently estimates longevity clinics at $5.35 billion.

Simply adding those figures produces about $68.6 billion.

We would not pretend that $68.6 billion is an exact market size. Clinics sell diagnostics. Some supplement sales may already appear inside broader anti-aging estimates. Different research firms also draw category boundaries differently.

Still, the order of magnitude is useful.

A $5 billion estimate is clearly too small if we include consumer anti-aging products. A trillion-dollar estimate becomes impossible to defend without pulling in huge adjacent industries.

The broad commercial longevity market therefore sits much closer to tens of billions than either extreme.

Is skincare still the biggest longevity business?

Yes. Skincare currently generates far more longevity-related revenue than biological-age tests, longevity clinics or experimental geroscience.

Grand View Research values anti-aging products at $55.6 billion, and the market is still dominated by familiar consumer categories such as facial serums, moisturizers, eye care and sun protection.

That gives the industry an odd shape. The most ambitious longevity companies are trying to reprogram cells, clear senescent cells or change pathways linked to aging. Most of the actual money, meanwhile, still comes from products people put on their skin.

A large part of today's longevity revenue has existed for decades under labels such as beauty, anti-aging and skincare. The newer part is the smaller layer being built around biological-age testing, preventive medicine, data-heavy memberships and geroscience.

For that reason, we include skincare in a broad commercial estimate but remove most of it when trying to measure the newer healthspan economy.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

How big are longevity supplements, diagnostics and clinics now?

The modern healthspan market already supports several multibillion-dollar categories, but it is still much smaller than skincare.

Anti-aging supplements were worth an estimated $4.8 billion in 2025, according to Grand View Research. Longevity diagnostics reached $2.8 billion, while The Business Research Company's newest estimate puts longevity clinics at $5.35 billion.

Those categories overlap, so adding them mechanically would exaggerate the total. A clinic membership may already include blood testing, imaging, biological-age testing and supplements.

The underlying businesses are becoming easier to see, though.

Grand View expects longevity diagnostics to reach $2.9 billion this year, with North America accounting for 47.3% of the previous year's revenue. The Business Research Company expects longevity clinics to grow from $5.35 billion to $9.55 billion by 2030.

Clinic offerings are also getting more elaborate. Fountain Life currently sells memberships built around whole-body and brain MRI, DEXA scans, biomarkers and physician care. At the premium end of the U.S. market, annual programs can run into tens of thousands of dollars.

This part of longevity has moved beyond a niche experiment. We would place the genuinely dedicated healthspan market somewhere in the low tens of billions rather than pretend every anti-aging dollar belongs here.

Dedicated longevity category	Latest market estimate	What customers are buying
Longevity clinics	$5.35B	Testing, imaging, physician care, prevention
Anti-aging supplements	$4.8B	Collagen, NAD-related products, resveratrol and similar products
Longevity diagnostics	$2.8B	Epigenetic age, telomeres, multi-omics and related testing
Longevity diagnostics in North America	~47% of global revenue	Premium testing and preventive-health services
Longevity clinic forecast for 2030	$9.55B	Broader adoption of personalized preventive care
Longevity diagnostics forecast for 2033	$4.5B	Wider use of biological and molecular testing
Anti-aging supplement forecast for 2033	$9.0B	Continued consumer spending on healthy-aging products

Do people really want to spend more on longevity?

Yes. Recent consumer research shows that healthy aging is already a mainstream priority, although people respond much better to concrete health benefits than to vague promises of living longer.

McKinsey's latest wellness research found that up to 60% of consumers across surveyed markets consider healthy aging a top or very important priority.

An earlier McKinsey survey produced an even stronger purchasing signal: around 70% of respondents in the U.S. and UK, and 85% in China, said they had bought more healthy-aging products than in previous years.

What people mean by longevity is also quite practical. They talk about keeping their energy, maintaining cognitive function, avoiding chronic disease and staying independent.

That helps explain why blood testing, continuous monitoring, full-body imaging, supplements and fitness products are easier to sell than an abstract promise of adding years to someone's life.

The strongest commercial products these days tend to offer something the customer can measure now: cholesterol, glucose, body composition, sleep, fitness, imaging results or a biological-age score.

The desire to live healthier for longer is clearly there. The harder question is which products can turn that desire into durable recurring revenue.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Is longevity already a global market?

Consumer longevity is global now, while expensive diagnostics and high-end preventive medicine remain heavily concentrated in richer markets.

North America represented 35.9% of anti-aging product revenue in Grand View Research's latest figures and 35.7% of anti-aging supplement revenue.

For longevity diagnostics, North America's share jumps to 47.3%.

That gap tells us quite a lot.

Skincare and supplements can be distributed cheaply and sold to very large populations. Whole-body MRI, multi-omics testing and concierge medicine require more money, infrastructure and clinical capacity.

Asia should become increasingly important. Grand View already expects Asia-Pacific to be the fastest-growing region in anti-aging supplements, while The Business Research Company also identifies Asia-Pacific as the fastest-growing longevity-clinic region.

Population aging gives that growth a long runway. The United Nations expects the number of people aged 65 and over to rise from 761 million in 2021 to 1.6 billion by 2050.

For now, though, the premium medical version of longevity remains much less global than the demographic trend behind it.

Does an aging population automatically create a huge longevity market?

No. More older people create enormous demand for better health, but most of their spending still belongs to ordinary healthcare and consumer industries.

The United Nations expects the global 65-plus population to more than double between 2021 and 2050.

A new Nature Aging analysis goes further into the underlying health burden. Looking at global disease data, researchers found that aging-related diseases already represent the largest part of the current global disease burden, including in lower-income countries.

That strengthens the economic case for addressing aging biology upstream.

But it does not mean every cancer treatment, hospital visit, pension payment or grocery purchase by an older person suddenly becomes longevity-industry revenue.

The commercial opportunity appears when companies build products specifically around maintaining health for longer: earlier diagnosis, disease prevention, preserving mobility, protecting cognition or eventually modifying the biology that drives several age-related diseases at once.

Population aging gives longevity a huge potential customer base. The dedicated industry selling to that customer base is still far smaller.

Is there a real market for longevity drugs yet?

The market for drugs approved specifically to slow biological aging is still effectively zero.

Nature Biotechnology recently reviewed the state of the field and found that no gerotherapeutic has been approved. The FDA still does not recognize aging itself as a disease indication with a dedicated regulatory pathway.

Several existing drugs are being studied because they may influence aging-related pathways. Metformin, rapamycin and related compounds, senolytics, NAD-related interventions and GLP-1 drugs have all attracted attention.

GLP-1s are especially interesting now because they have shown benefits across several conditions associated with aging. Nature Biotechnology recently asked whether they might eventually qualify as the first longevity drugs.

For the moment, their revenue still comes from approved indications such as obesity and diabetes rather than an aging indication.

Newer longevity companies face the same reality. Their clinical programs usually enter human testing through recognized diseases or organ-specific conditions.

So a forecast describing “longevity therapeutics” as a market worth tens of billions may include treatments for age-related diseases. That can be useful for estimating opportunity, but it tells us very little about current sales of medicines that actually slow aging.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

How close are longevity drugs to becoming real medicines?

Longevity biotech is much closer to human medicine than it was a few years ago, but we still do not know whether the most ambitious approaches will work in people.

The progress is real.

Retro Biosciences says it moved its RTR242 program from indication selection to first-in-human dosing in 15 months. NewLimit says its first cellular-reprogramming medicine is expected to enter human trials after the company reported reversing cellular age in old human liver cells in preclinical work.

Clinical researchers are also getting more serious about how geroscience trials should be run.

A recent expert-consensus study involving 28 specialists found support for endpoints based on age-related disease, physical function and patient-reported outcomes. The same experts were skeptical that blood biomarkers alone would be accepted as primary efficacy endpoints.

That is a major hurdle for the field.

A biological-age score can move quickly. Proving that a drug actually keeps people healthier, delays several diseases or preserves function is much harder and may require longer, larger trials.

The science has entered a much more interesting phase: humans are beginning to receive some of these interventions, while the proof needed for mainstream medicine remains ahead of us.

Why are investors putting billions into longevity before the drug market exists?

Investors are paying for the possibility that one aging intervention could eventually address several enormous diseases at once.

The amount of capital moving into the field has accelerated sharply.

A newly released Longevity.Technology report estimates that longevity-biotech investment jumped from $4.7 billion in 2024 to a record $18.4 billion in 2025. It says another $12.1 billion has already been invested during the current year.

That is almost $35 billion across less than three years under the report's biotech definition.

Individual companies show where the money is going.

NewLimit recently raised $435 million to move its reprogramming medicines toward human trials. Retro Biosciences announced the initial close of a new financing at a $1.8 billion pre-money valuation after taking its first clinical candidate into humans.

Altos Labs had already shown how much capital this area could attract when it launched with roughly $3 billion in committed funding.

Investors are plainly looking beyond today's clinic and supplement market. The bet is that therapies targeting aging biology could eventually compete inside major pharmaceutical categories such as cardiovascular disease, neurodegeneration and metabolic disease.

Recent biotech signal	Scale	What has actually happened
Longevity-biotech investment in 2024	$4.7B	Sector-wide estimate
Longevity-biotech investment in 2025	$18.4B	Record annual estimate
Investment reported so far this year	$12.1B	Capital continues to arrive at a high rate
NewLimit latest round	$435M	Financing ahead of planned human trials
Retro Biosciences latest valuation	$1.8B pre-money	First clinical candidate already in humans
Altos Labs launch funding	~$3B	Large-scale bet on cellular rejuvenation
NewLimit previous disclosed financing	$130M	Earlier funding for reprogramming medicines

Do billion-dollar longevity startups prove the market is already huge?

Billion-dollar longevity valuations mostly show how large investors think the future market could become, rather than how much revenue exists now.

NewLimit can raise $435 million before its first medicine reaches human trials because investors are valuing a scientific platform and the size of the possible payoff.

Retro is similar. Its latest $1.8 billion pre-money valuation reflects its pipeline, clinical progress and the possibility that its technologies work across several age-related conditions.

Those valuations cannot be added to market revenue.

They are closer to option prices: investors are paying today for a chance to own part of a potentially enormous future pharmaceutical business.

The gap between funding and product revenue is unusually wide in longevity.

At the consumer end, companies can already sell tests, memberships and supplements.

At the biotech end, investors can put hundreds of millions of dollars into a company years before it sells an approved medicine.

Mixing those two forms of economic activity makes the market look much more mature than it really is.

Could one successful longevity drug make this a massive market?

Yes. A drug that safely delays several age-related diseases at once could create a pharmaceutical market far larger than today's longevity industry.

The economic logic comes from the biology.

Cancer, cardiovascular disease, dementia, metabolic disease and frailty all rise strongly with age. Geroscience asks whether changing an upstream aging mechanism could reduce several of those risks together.

A new Nature Aging analysis reinforces how important that idea could become. Researchers found that aging-related diseases now make up the largest component of the global disease burden and argued that reducing them creates increasing returns because further health improvements become more valuable as people live longer and healthier lives.

An older Nature Aging economic model put a number on the theoretical upside. It estimated that slowing aging enough to add one year to U.S. life expectancy could create roughly $38 trillion of aggregate economic value. A ten-year improvement produced a theoretical value of about $367 trillion.

Those figures measure modeled social value rather than company sales.

Even so, they show why the commercial prize could become enormous. A therapy would only need to capture a small fraction of the health and economic value it creates to support a very large pharmaceutical business.

The opportunity is unusually large, while the clinical evidence required to unlock it remains unusually demanding.

Are the trillion-dollar longevity claims misleading?

Usually, yes, when they are presented as current market revenue.

AARP's latest Longevity Economy report says Americans aged 50 and over generated $12.5 trillion in annual economic activity in 2024.

The Global Wellness Institute puts the entire wellness economy at $6.8 trillion.

The Nature Aging model calculated tens of trillions of dollars of theoretical value from slower aging.

All three numbers are useful, but they answer different questions.

The AARP figure includes the wider economic contribution of older Americans. The wellness figure covers 11 broad sectors. The Nature Aging estimate is a model of society's willingness to pay for healthier, longer lives.

None tells us how much revenue longevity companies currently generate.

For market sizing, the cleanest approach is to keep current commercial spending, adjacent economic activity and theoretical future value in separate buckets. Once those numbers get mixed together, almost any trillion-dollar claim can be made to look plausible.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

So what is the longevity market actually worth today?

The broad longevity market is worth roughly $60 billion to $70 billion in current annual spending, while the newer healthspan market is probably closer to $10 billion to $20 billion.

The first range includes the large anti-aging consumer market, especially skincare, plus supplements, clinics and diagnostics. It captures what people are already willing to buy because they want to look younger, age better or stay healthier for longer.

The second range removes most conventional beauty spending and focuses on the businesses that better match what people now mean by “longevity”: dedicated clinics, biological-age and molecular testing, preventive-health memberships, targeted supplements and related services.

The pharmaceutical answer is completely different. Drugs approved specifically to modify biological aging still generate essentially no market revenue because no gerotherapeutic has received that approval.

Meanwhile, capital is moving far faster than sales. As seen above, longevity-biotech investment reached an estimated $18.4 billion last year and another $12.1 billion has already been reported this year. Investors increasingly believe the eventual drug market could dwarf today's consumer one.

So our best answer is around $60 billion to $70 billion for broad commercial longevity, perhaps $10 billion to $20 billion for the more focused healthspan economy, and effectively zero for an approved aging-drug market today.

The last category is also the one that could change the entire scale of the industry.